GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Tech & Admin support
    • Scientific Advisory Board
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases
      • IHC – Individual health care
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
  • Networks & Partnerships
  • Reports
    • GHTM
    • Scientific Advisory Board
    • FCT
Home / Archives for Kaiser R

Earlier initiation of antiretroviral treatment coincides with an initial control of the HIV-1 sub-subtype F1 outbreak among men-having-sex-with-men in Flanders, Belgium

  • Authors: Vinken L, Fransen K, Cuypers L, Alexiev I, Balotta C, Debaisieux L, Seguin-Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sönnerborg A, Vancutsem E, Vandamme AM, Van den Wijngaert S, Van Ranst M, Verhofstede C, Stadler T, Lemey P, Van Laethem K
  • Publication Year: 2019
  • Journal: Frontiers in Microbiology
  • Link: https://www.ncbi.nlm.nih.gov/pubmed/30972053

Human immunodeficiency virus type 1 (HIV-1) non-B subtype infections occurred in Belgium since the 1980s, mainly amongst migrants and heterosexuals, whereas subtype B predominated in men-having-sex-with-men (MSM). In the last decade, the diagnosis of F1 sub-subtype in particular has increased substantially, which prompted us to perform a detailed reconstruction of its epidemiological history. To this […]
Read More

State of the antiretroviral therapy in human immunodeficiency virus drug resistance: Science and technology knowledge gap

  • Authors: Boucher CA, Bobkova MR, Geretti AM, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Dorr P, Vandamme AM
  • Publication Year: 2018
  • Journal: AIDS Reviews
  • Link: https://www.ncbi.nlm.nih.gov/pubmed/29628515

Abstract Resistance to antiretroviral therapy (ART) threatens the efficacy of human immunodeficiency virus type 1 (HIV-1) treatment. We present a review of knowledge gaps in the science and technologies of acquired HIV-1 drug resistance (HIVDR) in an effort to facilitate research, scientific exchange, and progress in clinical management. The expert authorship of this review convened […]
Read More

State of the antiretroviral therapy in human immunodeficiency virus drug resistance: Surveillance and regional gaps

  • Authors: Boucher CA, Bobkova MR, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Vandamme AM, Dorr P
  • Publication Year: 2018
  • Journal: AIDS Reviews
  • Link: https://www.ncbi.nlm.nih.gov/pubmed/29628514

Abstract This article is the second of a two-part review aiming to identify gaps in the knowledge and management of human immunodeficiency virus type 1 drug resistance (HIVDR) from global and regional perspectives. Here, we examine the policy and programmatic gaps in HIVDR surveillance, the affected populations and settings, and implications for clinical practice. The […]
Read More

A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium

  • Authors: Alexiev I, Balotta C, Debaisieux L, Devaux C, Fransen K, García Ribas S, Gomes P, Incardona F, Kaiser R, Lemey P, Paraschiv S, Paredes R, Peeters M, Pineda-Peña AC, Ruelle J, Sayan M, Sönnerborg A, Van den Wijngaert S, Van Laethem K, Van Ranst M, Vancutsem E, Vandamme AM, Verhofstede C, Vinken L
  • Publication Year: 2017
  • Journal: Virus Evolution
  • Link: https://academic.oup.com/ve/article/3/suppl_1/vew036.020/4090767%20

HIV-1 non-B subtype infections have been observed in Belgium since the 1980s. However, subtype B predominates amongst men having sex with men (MSM), whereas other subtypes are mainly associated with sub-Saharan African migrants and heterosexual risk behavior. In the last decade, subtype F1 diagnoses have increased substantially in Belgium, representing 9% of newly diagnosed and […]
Read More

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe

  • Authors: Asboe D, Bansi L, Camacho R, Codoñer FM, De Luca A, Di Giambenedetto S, Dunn D, Fanti I, Ghisetti V, Kaiser R, Prosperi MCF, Sönnerborg A, Torti C, van de Vijver DC, Van Laethem K, Vandamme AM, Zazzi M
  • Publication Year: 2013
  • Journal: Journal of Infectious Diseases
  • Link: http://jid.oxfordjournals.org/content/early/2013/01/11/infdis.jit017.abstract

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20,323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.
Read More

  • 1
  • 2
  • Next Page »

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • E-mail
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Map

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2025 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok